We are live on ! Find out more
ALIM

Alimera Sciences
ALIM

Delisted

ALIM was delisted on the 13th of September, 2024.

Back to rankings

39 hedge funds and large institutions have $38.2M invested in Alimera Sciences in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more capital invested

Capital invested by funds: $25.6M → $38.2M (+$12.6M)

0% more funds holding

Funds holding: 39 → 39 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

Holders
39
Holders Change
–
Holders Change %
0%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
9
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$256K
2
Renaissance Technologies
Renaissance Technologies
New York
+$191K
3
BCM
Bridgeway Capital Management
Texas
+$101K
4
Citadel Advisors
Citadel Advisors
Florida
+$92.6K
5
CPA
Columbia Pacific Advisors
Washington
+$51.2K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$180K
2
BRF
B. Riley Financial
California
-$147K
3
SCM
Stonepine Capital Management
Oregon
-$65.1K
4
TRCT
Tower Research Capital (TRC)
New York
-$24.9K
5
VF
Virtu Financial
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$7.35M – – –
SCM
2
Stonepine Capital Management
Oregon
$6.87M -$65.1K -4,277 -1%
ACA
3
Avoro Capital Advisors
New York
$6.61M – – –
DM
4
Deerfield Management
New York
$6.42M – – –
PAI
5
Palo Alto Investors
California
$3.19M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.81M +$28.1K +1,847 +2%
Morgan Stanley
7
Morgan Stanley
New York
$1.23M -$396 -26 -0%
Renaissance Technologies
8
Renaissance Technologies
New York
$1.06M +$191K +12,540 +23%
BCM
9
Bridgeway Capital Management
Texas
$625K +$101K +6,667 +20%
RA
10
Royce & Associates
New York
$606K +$256K +16,806 +79%
JAM
11
JW Asset Management
Florida
$438K – – –
DMK
12
David M. Knott
$427K +$15.2K +1,000 +4%
BlackRock
13
BlackRock
New York
$307K -$1.78K -117 -0.6%
BRF
14
B. Riley Financial
California
$303K -$147K -9,640 -34%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$155K +$1.98K +130 +1%
BRWM
16
B. Riley Wealth Management
Tennessee
$148K +$37.9K +2,493 +37%
Northern Trust
17
Northern Trust
Illinois
$118K +$4.5K +296 +4%
Citadel Advisors
18
Citadel Advisors
Florida
$97K +$92.6K +6,089 New
WMSA
19
Weiss Multi-Strategy Advisers
New York
$89K -$396 -26 -0.5%
CPA
20
Columbia Pacific Advisors
Washington
$54K +$51.2K +3,365 New
Deutsche Bank
21
Deutsche Bank
Germany
$53K +$51.1K +3,360 New
KWM
22
Kingsview Wealth Management
Oregon
$50K +$47.5K +3,122 New
SO
23
STRS Ohio
Ohio
$46K – – –
Charles Schwab
24
Charles Schwab
California
$42K +$40K +2,627 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$27K -$639 -42 -2%
1
2

ALIM Hedge Fund Activity: Q1 2019 in Review

39 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Alimera Sciences (ALIM) for Q1 2019, worth a combined $38.2M — up 49% from $25.6M a quarter earlier.

Fund positioning in ALIM was balanced in Q1 2019: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 9 trimmed.

The largest buyer was Royce & Associates, adding an estimated $256K. The largest seller was OrbiMed, exiting entirely with an estimated $180K sold.

  • 39 institutional investors held Alimera Sciences (ALIM) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $38.2M of Alimera Sciences stock for Q1 2019, up 49% quarter-over-quarter.
  • 6 funds opened new Alimera Sciences positions in Q1 2019 and 6 closed out, a net change of 0 holders.
  • The largest Alimera Sciences buyer in Q1 2019 was Royce & Associates, an estimated $256K added.
  • The largest Alimera Sciences seller in Q1 2019 was OrbiMed, an estimated $180K sold.

Based on aggregated 13F filings for Q1 2019.